Triple antiviral therapy in HCV positive patients who failed prior combination therapy

Table 1 Baseline characteristics of patients (Information are not available for all patients) n (%)

Characteristic	All(n = 188)	PegIFN +RBV + AMA(n = 106)	IFN+RBV+AMA(n = 82)
Male/Female	146/42	79/27	67/15
Age
≤ 40 yr	42 (22)	23 (22)	19 (23)
> 40 yr	146 (78)	83 (78)	63 (77)
BMI
≤ 25 kg/m2	107 (64)	60 (65)	47 (63)
> 25 kg/m2	61 (36)	33 (35)	28 (37)
ALT
≤ 120 UI/L	107 (62)	64 (65)	43 (58)
> 120 UI/L	66 (38)	35 (35)	31 (42)
HCV genotype
1	147 (78)	82 (77)	65 (79)
2	21 (11)	12 (11)	9 (11)
3	8 (4)	7 (7)	1 (1)
4	12 (6)	5 (5)	7 (9)
HCV RNA
≤ 2 x 106 copies/mL	74 (73)	41 (76)	33 (69)
> 2 x 106 copies/mL	28 (27)	13 (24)	15 (31)
Stage
≤ 3	127 (69)	71 (70)	56 (68)
> 3	56 (31)	30 (30)	26 (32)
Grade
≤ 10	167 (92)	94 (91)	73 (92)
> 10	15 (8)	9 (9)	6 (8)

Table 2 Sustained virologic response for all treatment groups combined according to the baseline characteristics of patients

Characteristics	Sustained virologic response		P1
Genotype 1	32/147	22%	0.0085
Non 1	18/41	44%
Age ≤ 40 yr	13/42	31%	NS
> 40 yr	37/146	25%
BMI ≤ 25 kg/m2	32/107	30%	NS
> 25 kg/m2	12/61	20%
Stage ≤ 3	37/127	29%	NS
> 3	12/56	21%
Grade ≤ 10	42/167	25%	0.03
> 10	8/15	53%
ALT ≤ 120 UI/L	22/107	21%	0.03
> 120 UI/L	24/66	36%
HCV-RNA ≤ 2 × 106 copies/mL	23/74	31%	NS
> 2 × 106 copies/mL	7/28	25%
Previous Total IFN ≤ 500 MU	20/91	22%	NS
> 500 MU	25/82	30%

¹ Fisher's exact test; NS: Not significant.

Table 3 Sustained virologic response in patients treated with Peg IFN or standard IFN according to the baseline characteristics of patients

Characteristic	PegIFN+RBV+AMA		IFN+RBV+AMA		P
Genotype 1	21/82	26%	11/65	17%	NS
Non 1	13/24	54%	5/17	29%	NS
Age ≤ 40 yr	11/23	48%	2/19	11%	0.017
> 40 yr	23/83	28%	14/63	22%	NS
BMI ≤ 25 kg/m2	22/60	37%	10/47	21%	NS
> 25 kg/m2	8/33	24%	4/28	14%	NS
Stage ≤ 3	27/71	38%	10/56	18%	0.018
> 3	6/30	20%	6/26	23%	NS
Grade ≤ 10	28/94	30%	14/73	19%	NS
> 10	6/9	67%	2/6	33%	NS
ALT ≤ 120 UI/L	17/64	27%	5/43	12%	NS
> 120 UI/L	15/35	43%	9/31	29%	NS
HCV-RNA ≤ 2 × 106 copies/mL	15/41	37%	8/33	24%	NS
> 2 × 106 copies/mL	6/13	46%	1/15	7%	0.029

NS: Not significant.

Table 4 Reasons for treatment discontinuation

	PegIFN +RBV+ AMA(n = 106)	IFN+RBV+AMA(n = 82)
Treatment discontinuation for any	10 (9.4%)	17 (20.7%)
Reason1
Study drug noncompliance	2	11
Demyelinizing neuropathy	1
Depression	1	1
Erythema		1
Pulmonary fibrosis	1
Hyperthyroidism	1
Hyperthyroidism & Insomnia	1
Increased ALT		1
Leukopenia	1	3
Dyspnoea, Cough, Pruritus	1
Unknown reason	1

¹ Fisher’s exact test: P = 0.036.